Enhanced Cellular Immunity in Macaques Following a Novel Peptide Immunotherapy

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2005 Feb 26

PMID 15731268

Citations 15

Authors

S Chea

C J Dale

R De Rose

I A Ramshaw

S J Kent

Affiliations

Soon will be listed here.

Abstract

Advances in treating and preventing AIDS depend on understanding how human immunodeficiency virus (HIV) is eliminated in vivo and on the manipulation of effective immune responses to HIV. During the development of assays quantifying the elimination of fluorescent autologous cells coated with overlapping 15-mer simian immunodeficiency virus (SIV) or HIV-1 peptides, we made a remarkable observation: the reinfusion of macaque peripheral blood mononuclear cells, or even whole blood, pulsed with SIV and/or HIV peptides generated sharply enhanced SIV- and HIV-1-specific T-cell immunity. Strong, broad CD4+- and CD8+-T-cell responses could be enhanced simultaneously against peptide pools spanning 87% of all SIV- and HIV-1-expressed proteins-highly desirable characteristics of HIV-specific immunity. De novo hepatitis C virus-specific CD4+- and CD8+-T-cell responses were generated in macaques by the same method. This simple technique holds promise for the immunotherapy of HIV and other chronic viral infections.

Citing Articles

The dynamics of simian immunodeficiency virus after depletion of CD8+ cells.

Cardozo E, Apetrei C, Pandrea I, Ribeiro R Immunol Rev. 2018; 285(1):26-37.

PMID: 30129200 PMC: 6352983. DOI: 10.1111/imr.12691.

Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.

Lakhashe S, Byrareddy S, Zhou M, Bachler B, Hemashettar G, Hu S Vaccine. 2014; 32(48):6527-36.

PMID: 25245933 PMC: 4343195. DOI: 10.1016/j.vaccine.2014.08.065.

Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.

Kloverpris H, Jackson A, Handley A, Hayes P, Gilmour J, Riddell L PLoS One. 2013; 8(10):e74389.

PMID: 24124451 PMC: 3790804. DOI: 10.1371/journal.pone.0074389.

A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals.

Jackson A, Kloverpris H, Boffito M, Handley A, Atkins M, Hayes P PLoS One. 2013; 8(9):e73765.

PMID: 24069230 PMC: 3775760. DOI: 10.1371/journal.pone.0073765.

Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant.

Korsholm K, Karlsson I, Tang S, Brandt L, Agger E, Aagaard C PLoS One. 2013; 8(5):e63575.

PMID: 23691069 PMC: 3656914. DOI: 10.1371/journal.pone.0063575.

References

Barouch D, Fu T, Montefiori D, Lewis M, Shiver J, Letvin N . Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol Lett. 2001; 79(1-2):57-61. DOI: 10.1016/s0165-2478(01)00266-8. View

Maecker H, Dunn H, Suni M, Khatamzas E, Pitcher C, Bunde T . Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001; 255(1-2):27-40. DOI: 10.1016/s0022-1759(01)00416-1. View

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

Douek D, Brenchley J, Betts M, Ambrozak D, Hill B, Okamoto Y . HIV preferentially infects HIV-specific CD4+ T cells. Nature. 2002; 417(6884):95-8. DOI: 10.1038/417095a. View

Appay V, Zaunders J, Papagno L, Sutton J, Jaramillo A, Waters A . Characterization of CD4(+) CTLs ex vivo. J Immunol. 2002; 168(11):5954-8. DOI: 10.4049/jimmunol.168.11.5954. View

Dale C, Liu X, De Rose R, Purcell D, Anderson J, Xu Y . Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology. 2002; 301(1):176-87. DOI: 10.1006/viro.2002.1589. View

Oosterwijk-Wakka J, Tiemessen D, Bleumer I, de Vries I, Jongmans W, Adema G . Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother. 2002; 25(6):500-8. DOI: 10.1097/00002371-200211000-00006. View

Lu W, Wu X, Lu Y, Guo W, Andrieu J . Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med. 2002; 9(1):27-32. DOI: 10.1038/nm806. View

Smithers M, OConnell K, MacFadyen S, Chambers M, Greenwood K, Boyce A . Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother. 2003; 52(1):41-52. PMC: 11034263. DOI: 10.1007/s00262-002-0318-y. View

10.

Russell N, Hudgens M, Ha R, Havenar-Daughton C, McElrath M . Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis. 2003; 187(2):226-42. DOI: 10.1086/367702. View

11.

Coles R, Jones C, Brooks A, Cameron P, Heath W, Carbone F . Virus infection expands a biased subset of T cells that bind tetrameric class I peptide complexes. Eur J Immunol. 2003; 33(6):1557-67. DOI: 10.1002/eji.200323715. View

12.

Karlsson A, Martin J, Younger S, Bredt B, Epling L, Ronquillo R . Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods. 2003; 283(1-2):141-53. DOI: 10.1016/j.jim.2003.09.001. View

13.

Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W . Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMC: 236393. DOI: 10.1128/JVI.68.7.4650-4655.1994. View

14.

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

15.

Kent S, Greenberg P, HOFFMAN M, Akridge R, McElrath M . Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure. J Immunol. 1997; 158(2):807-15. View

16.

Aichele P, Oehen S, Odermatt B, Zinkernagel R, Hengartner H, Pircher H . Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity. 1997; 6(5):519-29. DOI: 10.1016/s1074-7613(00)80340-4. View

17.

Rosenberg E, Billingsley J, Caliendo A, Boswell S, Sax P, Kalams S . Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997; 278(5342):1447-50. DOI: 10.1126/science.278.5342.1447. View

18.

Kent S, Zhao A, Best S, Chandler J, Boyle D, Ramshaw I . Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol. 1998; 72(12):10180-8. PMC: 110562. DOI: 10.1128/JVI.72.12.10180-10188.1998. View

19.

Oehen S . Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol. 1998; 161(10):5338-46. View

20.

Schmitz J, Kuroda M, Santra S, Sasseville V, Simon M, Lifton M . Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999; 283(5403):857-60. DOI: 10.1126/science.283.5403.857. View